OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.